Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track CLDX with free AI briefings, catalyst countdowns, and dilution alerts.

CLDX · Celldex Therapeutics, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$650.3M Cash on Hand
31.9mo Cash Runway
Follow CLDX by email Get an email when CLDX reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about CLDX, unsubscribe in one click. Privacy

📣 What CLDX Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Phase I: Glembatumumab Vedotin Squamous Cell Carcinoma of the Lung Phase 1/2 · NCT02713828 Terminated
Recombinant Flt3 Ligand Non-small Cell Lung Cancer (NSCLC) Phase 2 · NCT02839265 Completed
Glembatumumab Vedotin (CDX-011) Melanoma Phase 2 · NCT02302339 Terminated
6 Melanoma Helper Peptide Vaccine Melanoma Phase 1/2 · NCT04364230 Completed
Human CMV pp65-LAMP mRNA-pulsed autologous DCs Glioblastoma Phase 2 · NCT03688178 Active not recruiting
Keyhole Limpet Hemocyanin Glioblastoma Phase 2 · NCT01498328 Completed
NeoAg-mBRAF Melanoma Phase 1/2 · NCT04364230 Completed
Phase II: Glembatumumab Vedotin Squamous Cell Carcinoma of the Lung Phase 1/2 · NCT02713828 Terminated
PolyICLC Melanoma Phase 1/2 · NCT04364230 Completed
Rindopepimut Glioblastoma Phase 2 · NCT01498328 Completed
Trametinib daily Until PD Melanoma Phase 1/2 · NCT03580382 Terminated
Unpulsed DCs Glioblastoma Phase 2 · NCT03688178 Active not recruiting
Varlilumab (CDX-1127) Glioblastoma Phase 2 · NCT03688178 Active not recruiting
Epacadostat Fallopian Tube Carcinoma Phase 1/2 · NCT02166905 Completed
Anti-CD40 Agonist Monoclonal Antibody CDX-1140 Ovarian Clear Cell Adenocarcinoma Phase 2 · NCT05231122 Recruiting
anti-CD40 antibody (CDX-1140) Non Small Cell Lung Cancer Phase 1/2 · NCT04491084 Terminated

Also used in these trials (approved or third-party drugs, not CLDX's own candidates): Incomplete Freund's Adjuvant, Pembrolizumab, Poly ICLC, Temozolomide, Bevacizumab, Capecitabine, Nivolumab, Decitabine.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

CLDX holds $650.3M in cash and short-term investments (as of Sep 30, 2026) and burns about $61.2M/quarter from operations, an estimated runway of 31.9 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 17 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when CLDX files for a raise →

👥 Who Owns CLDX

Insiders 0.1% Institutions (349 holders) 99.9% Public and other holders 0%
HolderTypeShares% of sharesAs of
Wellington Management Group LLP Institution (13G, 5%+) 10,951,399 13.94% 2026-09-30
FMR LLC Institution (13G, 5%+) 8,411,905 10.71% 2026-09-30
T. Rowe Price Associates, Inc. Institution (13G, 5%+) 4,686,187 5.97% 2026-06-30
Vanguard Capital Management Institution (13G, 5%+) 3,446,795 4.39% 2026-03-31
Samuel Bates Martin
SVP AND CFO · +232,815 options
Insider 32,942 0.04% 2026-01-02
Freddy A. Jimenez
SVP & GENERAL COUNSEL · +168,000 options
Insider 30,796 0.04% 2025-12-04
Richard M. Wright
Former Officer · +7,875 options
Insider 20,833 0.03% 2025-11-13
Ronald Pepin
SR. VP & CBO · +45,000 options
Insider 20,097 0.03% 2025-12-15

Share count 78,545,051 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full CLDX picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for CLDX and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.